Prediction of relapse in myelin oligodendrocyte glycoprotein antibody-associated disease: external validation of the MOG-AR score - PubMed
4 hours ago
- #Risk Score Validation
- #MOGAD
- #Relapse Prediction
- The study externally validates the MOG-AR score for predicting relapses in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
- Included 284 MOGAD patients with a median disease duration of 4.7 years; 38% experienced a relapse within 3 years of onset.
- MOG-AR score showed suboptimal performance in predicting relapses, with an area under the ROC curve of 0.58.
- Calibration assessment indicated overestimation of relapse probabilities by the MOG-AR score.
- Highlights the need for better predictive biomarkers and tools to guide treatment strategies near disease onset.